公开(公告)号：JPH0476522A

公开(公告)日：1992-03-11

申请号：JP19014490

申请日：1990-07-18

Applicant: HOECHST JAPAN

Inventor： MURAKAMI MIKIO ,  HARADA TAKAMASA

IPC: C08G63/60 ,  C09K19/02 ,  C09K19/56 ,  G02F1/1337

Abstract: PURPOSE:To obtain an oriented film having a high degree of liquid crystal orienting power by using polyester having the specific compsn. exhibiting solubility for general solvents. CONSTITUTION:The polyester having the repeating units expressed by formulas I, II (where Ar is a bivalent group contg. at least one arom. group) and III (where Ar' may be the same or different as Ar and is of the same definition as Ar) is used as the oriented film material on at least one opposite surface between substrates. A contrast is increased in this way and a grade is improved.

公开(公告)号：JPH03197475A

公开(公告)日：1991-08-28

申请号：JP33625689

申请日：1989-12-27

Applicant: HOECHST JAPAN

Inventor： SENDA SHUNJI ,  SETO HARUO

IPC: A61K31/335 ,  A61K31/336 ,  A61P35/00 ,  A61P35/02 ,  C07D303/31 ,  C07D303/32 ,  C12P17/02 ,  C12R1/465

Abstract: NEW MATERIAL:A benzanthracene compound expressed by the formula. USE:An antitumor antibiotic substance useful as an anticancer agent. PREPARATION:A microorganism, belonging to the genus Streptomyces and capable of producing the benzanthracene compound (substance 683) expressed by the formula is cultured in a culture medium such as glucose or glycerol under aerobic conditions by a conventional method for 2-10 days and the resultant culture is treated by extraction with a solvent, purification, recrystallization, etc., to afford the compound expressed by the formula. Properties, color and appearance of the substance 683; white powder. Elementary analysis value; C, 67.04%; H, 5.71%; N; 0%. Molecular weight; 356. Molecular formula; C20H20O6. Melting point; 204-206 deg.C (decomposition). Specific rotatory power; +170 deg.C (C=0.023, methanol).

公开(公告)号：JPH03163019A

公开(公告)日：1991-07-15

申请号：JP21033490

申请日：1990-08-10

Applicant: HOECHST JAPAN

Inventor： TANAKA SHUNZO ,  URURITSUHI GEEBERUTO ,  HAYASHI MASAAKI ,  MORIOKA HIROKO

IPC: C07D487/04 ,  A61K31/00 ,  A61K31/495 ,  A61K31/52 ,  A61K31/522 ,  A61P1/00 ,  A61P1/04 ,  C07D473/04

Abstract: PURPOSE:To obtain an antipeptic ulcer agent, containing a specific substituted xanthine derivative as an active ingredient and having excellent antiulcer action with low toxicity. CONSTITUTION:The objective substance obtained by using a compound expressed by formula I [either of R1 and R3 is formula II (m is 1-5; R4 is 1-4C alkyl) and the other is H, OH or 1-8C alkyl or 3-6C alkenyl which can be substituted with 1-4C alkoxyl; R2 is 1-4C alkyl], mixing the compound with pharmacologically acceptable additives and preparing a pharmaceutical according to a conventional method. The aforementioned agent can be prepared in the form of tablet, sugar-coated tablet, pill, capsule, powder, granule, suppository, injection, etc., and dose thereof is 100-900mg/60kg body weight per day. The agent is capable of exhibiting excellent effects on ulcer caused by mucosal irritating substances, e.g. ethanol or especially ulcer caused by stress.

公开(公告)号：JPH01211524A

公开(公告)日：1989-08-24

申请号：JP3548488

申请日：1988-02-19

Applicant: HOECHST JAPAN

Inventor： EAHARUTO BORUFU ,  URURITSUHI GEEBERUTO ,  HARARUTO FURURERU ,  TANAKA SHUNZO ,  GOTO MASAYOSHI ,  SAKURAI MASAO

IPC: A61K31/52 ,  A61K31/522 ,  A61P1/04 ,  C07D473/04 ,  C07D473/06

Abstract: PURPOSE:To obtain an antipeptic ulcer agent, containing a specific xanthine derivative and having excellent remedial effects with high safety. CONSTITUTION:An antipeptic ulcer agent containing a compound expressed by formula I [R1 and R3 are 1-8C alkyl, 3-6C alkenyl, formula II-IV (R4 and R5 are H or 1-2C alkyl; R6 is 1-4C alkyl; m, n and p are 1-6); R2 is 1-2C alkyl, provided that either of R1 and R3 is formula II or III or R3 is formula IV], e.g., 1-allyl-3-ethyl-7-(5,6-dihydroxyhexyl)-xanthine, as an active ingredient. The dose of the above-mentioned compound is 300-900mg/60kg body weight, preferably 150-600mg/60kg body weight.

公开(公告)号：JPH01193229A

公开(公告)日：1989-08-03

申请号：JP1576188

申请日：1988-01-28

Applicant: HOECHST JAPAN

Inventor： HIRAHARA KEIZO

IPC: A61K38/43 ,  A61K31/715 ,  A61K38/46 ,  A61K38/48 ,  A61K38/55 ,  A61P7/02 ,  C12N9/64

Abstract: PURPOSE:To obtain an anticoagulant, containing protein C and heparin and, as necessary, further antithrombin III and having extremely strong anticoagulant action and high safety. CONSTITUTION:An anticoagulant containing protein C or activated protein C and heparin or protein C or activated protein C and heparin and antithrombin III as active ingredients. The above-mentioned pharmaceutical is preferably administered by injection or drip infusion and the amounts of the ingredients in a carrier are 2-20mug/ml protein C or activated protein C, 0.1-1.0 ups units/ ml heparin and 140-300mug/ml antithrombin III. The dose thereof is administered at a time so as to provide the total amount of proteins in the active ingredients within the range of 5mg-1g for an adult weighing 60kg.

公开(公告)号：JPS6486875A

公开(公告)日：1989-03-31

申请号：JP24504287

申请日：1987-09-29

Applicant: HOECHST JAPAN

Inventor： TOBA MARI ,  HASHIMOTO TAMOTSU

IPC: C12N15/09 ,  C12N1/20 ,  C12N15/00 ,  C12N15/65 ,  C12N15/68 ,  C12N15/71 ,  C12R1/19

Abstract: PURPOSE:To obtain a DNA, having a nonsense code in a coding region and capable of expressing streptomycin sensitive gene. CONSTITUTION:It is found that a recombinant molecule is a directly selective streptomycin-sensitive plasmid and expression of the sensitive gene is capable of completing a vector (designated as pHSG673 and pHSG683) which can be switched on and off by culture medium condition and species of a host microorganism and has many cloning sites and hardly forming nonrecombinant molecules as the background. One specific example of the DNA has an inductive promoter capable of regulating the expression on the upstream side of the streptomycin-sensitive gene.

公开(公告)号：JPS6463867A

公开(公告)日：1989-03-09

申请号：JP21907987

申请日：1987-09-03

Applicant: HOECHST JAPAN

Inventor： KATO MASAKAZU ,  KUROSAWA KAYOKO ,  TANAKA SHIGEAKI

IPC: G01N33/50 ,  G01N33/574

Abstract: PURPOSE:To detect cancer with high accuracy, by measuring the concn. ratio of the transforming gross factor and epithelial cell growth factor in body fluid or urine. CONSTITUTION:An urine specimen is centrifugally separated to remove an insoluble substance and subsequently freeze-dried and dissolved in 1% acetic acid to perform dialysis. The dialyzed solution is conc. under decompression so that final creatinine concn. is controlled to 100mg/l, and the concn. of a transforming gross factor alpha (TGF-alpha) and that of an epthlial cell growth factor (EGF) are measured by an immunochemical measuring method. Then, the concn. ratio of TGF-alpha/EGF is calculated. The average TGF-alpha/EGF value in urine is 0.78 in a cancer patient and 0.011 in a healthy person and a clear boundary can be provided in the vicinity of 0.035.

公开(公告)号：JPS6449961A

公开(公告)日：1989-02-27

申请号：JP20506987

申请日：1987-08-20

Applicant: HOECHST JAPAN

Inventor： JITSUKAWA TOMOFUMI ,  NAKAJIMA AKIKO ,  WATANABE HIROSHI

IPC: A61K39/00 ,  G01N33/531 ,  G01N33/543

Abstract: PURPOSE:To decrease the quantity of an antigen, etc., required in a depositing stage by fixing the antigen or antibody in a soln. state to a solid carrier in the co-presence of protein heterogeneous from the antigen or antibody, thereby constituting the carrier of the antigen or antibody. CONSTITUTION:Western horse-radish peroxidase HRPO is double double diluted with a phosphoric acid buffer physiological salt soln. PBS. One thereof is held intact and the other is mixed with 5.6mug/ml bovine serum albumin BSA at 1:1 volumetric ratio to the PBS soln. to prepare 10, 5, 2.5, 1.25, 0.625, 0.313, 0.156mug/ml solns. The soln. is dispensed by 60mul each into each well and is held for 1hr at room temp. to execute coating. The soln. is washed 5 times with PBS and 60mul citric acid buffer soln. of o-phenylene diamine is added thereto so that the soln. colors. The coloration reaction is stopped by adding 60mul 2M sulfuric acid to the soln. after 20-40min. The results of the measurements are shown in the figure.

公开(公告)号：JPS6425786A

公开(公告)日：1989-01-27

申请号：JP20906687

申请日：1987-08-21

Applicant: HOECHST JAPAN

Inventor： OSAKI TSUTOMU ,  SAKAKIBARA NISAKU ,  KURIKI TAKEO

IPC: A61K31/54 ,  A61P9/08 ,  A61P9/12 ,  C07D513/04

Abstract: NEW MATERIAL:The 1,3,6,7-tetrahydro-7-oxo-imidazo[4,5-C][1,2,6]thiadiazine 2-oxide derivative of formula I [R1, R2 and R4 are (substituted)alkyl, aryl or aralkyl; R3 is H, halogen, (substituted)alkyl, (substituted)aryl or (substituted) aralkyl]. EXAMPLE:1-Hexyl-1,3,6,7-tetrahydro-3,6-dimethyl-7-oxo-imidazo[4,5-C][1 ,2,6]thia diazine 2-oxide. USE:A hypotensor and vasodilator. PREPARATION:An imidazole derivative of formula II is made to react with a thionyl halide and, as necessary, the obtained compound is made to react with a halogenating agent.

公开(公告)号：JPS63263083A

公开(公告)日：1988-10-31

申请号：JP9634187

申请日：1987-04-21

Applicant: HOECHST JAPAN

Inventor： TAKAHASHI MIKIKO ,  MOTOKAWA HIDENORI ,  IWASAKI WAKAKO ,  TONE MASAHIDE ,  IWAKI AKIKO ,  TAKESHITA ATSUSHI ,  OTSUBO MASAYUKI ,  HASHIMOTO TAMOTSU

IPC: C12N15/09 ,  C07K14/00 ,  C07K14/81 ,  C12N1/20 ,  C12N5/10 ,  C12N9/64 ,  C12P21/02 ,  C12R1/19 ,  C12R1/91

Abstract: PURPOSE:To provide a human protein C gene free from intron part, containing a number of newly introduced restriction enzyme recognition sites, composed of partial substitute for synthetic DNA fragment and easily treatable by protein engineering operation. CONSTITUTION:The base sequence of a human protein C protein is varied by using a known base sequence as a base for about 2/3 of the protein from N-terminal while keeping the coded amino acids unchanged. The above region is supposed to be important in the expression and function of human protein C protein. The human protein C is divided by this process into 30 small DNA fragments each having a length of 33-80 nucleotides and designed to have restriction enzyme recognition sites at both ends. The divided small fragments are individually synthesized, subsequently linked with each other and cloned to obtain a synthetic part. The remaining part corresponding to 1/3 of the protein and originated from chromosome gene is linked with the above synthetic part using BamHI-HaeII fragments of the 8th exon which is the longest exon of the chromosome gene of the protein C. The objective gene coding 1389 human protein C and free from intron part can be produced by this process.